Epidermal growth factor receptor (EGFR) mutations are the second most common oncogenic
driver event in non-small cell lung cancer (NSCLC). Classical activating mutations (exon 19 …

Inframe insertions of three or more base pairs in exon 20 of the epidermal growth factor
receptor (EGFR) gene were among the first EGFR mutations to be identified as oncogenic …

Circulating tumour DNA (ctDNA) analysis facilitates studies of tumour heterogeneity. Here
we employ CAPP-Seq ctDNA analysis to study resistance mechanisms in 43 non-small cell …

Purpose Epidermal growth factor receptor (EGFR)–tyrosine kinase inhibitors have proven
efficacy in advanced non–small-cell lung cancer (NSCLC). We hypothesized that erlotinib …

Introduction: Adenocarcinoma is the most common histologic type of lung cancer. To
address advances in oncology, molecular biology, pathology, radiology, and surgery of lung …

Decades of research in molecular oncology have brought about promising new therapies
which are designed to target specific molecules which promote tumor growth and survival …

Purpose The results of the Iressa Pan-Asia Study (IPASS), which compared gefitinib and
carboplatin/paclitaxel in previously untreated never-smokers and light ex-smokers with …

Introduction: Cancer is a devastating disease; however, several therapeutic advances have
recently been made, wherein EGFR and its family members have emerged as useful …

Background Previous, uncontrolled studies have suggested that first-line treatment with
gefitinib would be efficacious in selected patients with non–small-cell lung cancer. Methods …

Epidermal growth factor receptor (EGFR)-mutant non-small-cell lung cancer (NSCLC) was
first recognized in 2004 as a distinct, clinically relevant molecular subset of lung cancer. The …